Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines
Both vaccination strategies are superior to no vaccination, producing more health benefits at lower costs. QALYs gained are higher with PHiD-CV but at higher direct costs. Results are most sensitive to assumptions about PCV10-SII vaccine price.
Authors
- Ru Han (ORCID: https://orcid.org/0000-0002-4851-1462)
- Gyneth Lourdes Bibera (ORCID: https://orcid.org/0000-0001-8512-6857)
- Olakunle Oladehin (ORCID: https://orcid.org/0000-0002-6151-1467)
- Nurilign Ahmed (ORCID: https://orcid.org/0000-0003-3953-7473)
- E Ramírez Ortiz (ORCID: https://orcid.org/0009-0002-2377-8707)
- Alexander Rodríguez‐López (ORCID: https://orcid.org/0000-0001-5409-3466)
- Jorge A. Gómez (ORCID: https://orcid.org/0000-0001-5459-4973)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- Taguig City University (PH)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1007/s40121-025-01162-x
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00